Hormone Replacement Therapy Market Analysis | CMI - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Hormone Replacement Therapy Market Analysis | CMI

Description:

Read here the latest updates on the Hormone Replacement Therapy Market Analysis published by CMI team – PowerPoint PPT presentation

Number of Views:2
Date added: 25 September 2020
Slides: 15
Provided by: Shweta2707
Category: Other

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Hormone Replacement Therapy Market Analysis | CMI


1
  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • COVID-19 Impact Tracker

2
HORMONE REPLACEMENT THERAPY MARKET ANALYSIS
  • Hormone Replacement Therapy Market, by Therapy
    Type (Estrogen Replacement Therapy, Human Growth
    Hormone (HGH) Replacement Therapy, Thyroid
    Replacement Therapy, and Testosterone Replacement
    Therapy), by Route of Administration (Oral,
    Parenteral, and Others), by Application
    (Hypothyroidism, Male Hypogonadism, Growth
    Hormone Deficiency, Menopause, and Others), by
    Distribution Channel (Hospital Pharmacies, Retail
    Pharmacies, and Online Pharmacies), and by Region
    (North America, Latin America, Europe, Asia
    Pacific, Middle East, and Africa) - Size, Share,
    Trends, and Forecast to 2026
  • The global hormone replacement therapy market
    size was valued at US 10.58 billion in 2017 and
    is expected to witness a CAGR of 5.2 over the
    forecast period (2018 2026).

3
Global Hormone Replacement Therapy Market Share
() Analysis, By Therapy Type 2017
4
Market Drivers
  • Increasing prevalence of various chronic
    conditions are expected to drive growth of the
    Hormone Replacement Therapy Market
  • Increasing prevalence of hypogonadism in adult
    men worldwide is expected to drive growth of the
    hormone replacement therapy market.
  • According to the European Association of Urology
    2016 report, in middle-aged men, the incidence of
    hypogonadism varies from 2.1 to 12.8. The
    incidence of low testosterone and symptoms of
    hypogonadism in men aged 40-79 varies form 2.1
    to 5.7, in Europe.
  • Ease in access and government support for
    research and development activities is expected
    to aid in growth of the hormone replacement
    therapy market. Financial help by NGOs such as
    the National Gaucher Society help patients
    receive enzyme replacement therapy that are
    costly.

5
Hormone Replacement Therapy Market Restraints
  • Stringent regulations proposed by the U.S. Food
    and Drug Administration (FDA) regarding the
    application of hormone replacement products,
    owing to increasing risk of adverse
    cardiovascular diseases is expected to hamper
    growth of the hormone replacement therapy market
    over the forecast period.
  • In February 2018, the U.S. FDA updated policies
    and stated that testosterone replacement product
    manufacturers need to change the labelling to
    inform the patients about possible increased risk
    of heart attack and stroke.
  • Furthermore, in January 2018 committee meeting,
    the FDA proposed the regulation demanding
    testosterone manufacturers to conduct a
    post-marketing randomized, double-blind,
    placebo-controlled trial, before marketing the
    product to determine whether this therapy
    increases major adverse cardiovascular diseases
    such as myocardial infarction and stroke or not.

6
Hormone Replacement Therapy Market - Regional
Insights
  • On the basis of region, the global hormone
    replacement therapy market is segmented into
    North America, Latin America, Europe, Asia
    Pacific, Middle East, and Africa. North America
    is expected to hold dominant position in the
    global hormone replacement therapy market, owing
    to continuous launch of various generic products
    for hormone replacement therapies by
    manufacturers.
  • Furthermore, Europe is expected to be the second
    largest contributor to the hormone replacement
    therapy market, in terms of revenue and is
    expected to gain significant traction in the near
    future. This is owing to launch of new drugs and
    therapies to combat secondary hyperparathyroidism
    and presence of significant population suffering
    from the disease in this region.
  • For instance, in December 2016, Amgens drug
    etecalcetide (Parsabiv) received marketing
    approval in Europe by the European Commission for
    the treatment of secondary hyperparathyroidism in
    adult patients with chronic kidney diseases.

7
  • Asia Pacific is expected to witness fastest
    growth over the forecast period, owing to
    increasing healthcare associated issues with
    rising incidence of chronic diseases, high
    prevalence of hypogonadism in men with type II
    diabetes mellitus, and rising prevalence of
    diabetes population in this region.
  • For instance, according to the International
    Diabetes Federation (IDF) Diabetes Atlas 2017,
    number of people suffering from diabetes aged
    between 20 to 79 years in South East Asia region
    and Western Pacific region in 2017, was 82
    million and 159 million, respectively.

8
Global Hormone Replacement Therapy Market Value
(US Mn) Y-o-Y Growth ()
9
Hormone Replacement Therapy Market - Competitive
Landscape
  • Manufacturers are focusing on developing generic
    versions of various drugs for the treatment of
    certain disorders that are highly prevalent in
    women such as hypothyroidism. For instance, Teva
    Pharmaceutical Industries Ltd. launched generic
    version of Vagifem (estradiol vaginal inserts),
    10 mcg in the U.S. on 24, July 2017. Estradiol
    vaginal inserts are an estrogen indicated for the
    treatment of atrophic vaginitis due to menopause.
  • Moreover, on December 29, 2017, Mylan N.V. got
    the U.S. FDA approval for its Abbreviated New
    Drug Application (ANDA) for Estradiol Vaginal
    Cream USP, 0.01 and thus, the company launched
    this drug in the U.S. This cream is the first
    generic version of Allergan's Estrace Cream,
    indicated for the treatment of vulvar and vaginal
    atrophy.
  • Mylan is one of the few companies that offers
    Estradiol in four delivery systems cream, gel,
    transdermal patch, and tablet. This provides
    greater benefit to healthcare professionals and
    patients, and brings long-term sustainability to
    their business.

10
Key Players
  • Key players operating in the global hormone
    replacement therapy market include Novartis AG,
    Abbott Laboratories, Mylan N.V., Merck KgaA,
    Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx
    Pharmaceuticals, Teva Pharmaceutical Industries
    Ltd., Amgen, Inc., and Eli Lilly and Company.

11
  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Reference https//www.coherentmarketinsights.com
    /market-insight/hormone-replacement-therapy-market
    -2079

12
About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

13
Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
    U.S.
  • Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

14
  • Thank You!
  • Kindly follow CMI Social Media Profiles
    for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com